Press Release Archives

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization       February 27, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with aContinue reading “Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization”

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus       February 26, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) toContinue reading “UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus”

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus       February 26, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate aContinue reading “Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus”

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders       January 30, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN),today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent uponContinue reading “Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders”

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue       January 29, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones includingContinue reading “Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue”

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025       January 12, 2026   Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continuedContinue reading “Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025”

Tevogen CEO Donates Shares to Support Education for Underprivileged Children       December 22, 2025   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, aContinue reading “Tevogen CEO Donates Shares to Support Education for Underprivileged Children”

Tevogen CEO Donates Personal Shares to Support Local Fire Department       December 19, 2025   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. BethelContinue reading “Tevogen CEO Donates Personal Shares to Support Local Fire Department”

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock       December 11, 2025   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stockContinue reading “Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock”

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine     December 9, 2025   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board ofContinue reading “Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine”